Skip to content

News Hub

The latest breaking stories

Access up-to-date news and information on a wide range of press releases including business, finance, technology, healthcare, entertainment, and more.

NewsMatch Alert

Discover the most important & comprehensive stories delivered directly to you daily.

  • Business Company News
  • 20/10/2025
  • 21:26
Staffbase

Staffbase and Cornerstone partner to bring learning content to frontline workers

New integration will deliver personalized, AI-powered learning, compliance, performance, and talent marketplace solutions to millions of non-desk employees worldwideNEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Staffbase, the first AI-native employee experience platform, today announced a strategic partnership with Cornerstone, a leader in workforce agility solutions. The partnership aims to help organizations deliver essential training and development opportunities to their entire workforce, especially hard-to-reach frontline employees.Non-desk workers represent a significant share of the workforce in sectors such as manufacturing, retail, healthcare, and transportation. Yet they often remain disconnected from corporate infrastructure like learning, compliance, performance and talent marketplace systems, while…

  • Medical Health Aged Care
  • 20/10/2025
  • 21:16
BeOne Medicines Ltd.

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

New data from two pivotal TEVIMBRA studies – RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in both NSCLC and ES-SCLCEarly data from investigational HPK1 inhibitor BGB-26808, in combination with TEVIMBRA, show promise in advanced solid tumors SAN CARLOS, Calif.--BUSINESS WIRE--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of data from two pivotal Phase 3 trials – RATIONALE-307 and 312 – offering new evidence of the benefits of its PD-1 inhibitor, TEVIMBRA® (tislelizumab), at the European Society of Medical Oncology 2025 Congress (ESMO 2025) in Berlin, Germany, October…

  • Information Technology
  • 20/10/2025
  • 21:11
Datavault AI Inc.

Datavault AI (NASDAQ: DVLT) Partners with Max International AG to Launch Swiss Digital RWA Exchange, Overcoming Barriers to Institutional Tokenization

Landmark Collaboration Harnesses Patented AI, Swiss Regulatory Fortress, and Fiduciary Expertise to Tokenize $1 Trillion1 + Global RWA Market, Anchored in Zurich’s Gold HubBEAVERTON, Ore., Oct. 20, 2025 (GLOBE NEWSWIRE) -- via IBN -- Datavault AI Inc. (NASDAQ: DVLT), a pioneer in patented AI-driven blockchain for secure data and asset monetization, today announces a strategic partnership with Max International AG as its licensed partner. This collaboration will deploy and manage a Switzerland-based Swiss Digital RWA Exchange aimed at maximizing the advantages presented by Switzerland’s robust digital regulatory frameworks. Switzerland is the home of SIX Digital Exchange (SDX)—NASDAQ’s longstanding technological ally…

  • Information Technology
  • 20/10/2025
  • 20:56
Golpo

Brothers, 19 and 20, Stanford dropouts, raise $4.1M in oversubscribed seed round to build Golpo AI and reimagine AI video generation

Golpo AI secures oversubscribed seed round to transform communication through interactive AI videosSAN FRANCISCO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Golpo, the AI-powered platform that transforms documents and prompts into interactive explainer videos, announced today it has raised $4.1 million in a heavily oversubscribed seed round led by BNVT Capital (spin out from the Gates Foundation and Hedosophia), alongside Emergence Capital, Y Combinator, Afore Capital and others. The raise attracted overwhelming investor demand, forcing the founders to turn away significant additional capital.Golpo was founded by brothers Shraman Kar (19) and Shreyas Kar (20) who dropped out of their computer science…

  • Travel Tourism
  • 20/10/2025
  • 20:26
Hong Kong Tourism Board

A Gastronomic Extravaganza: World-Renowned Chefs and Fine Wines Unite at Hong Kong Wine & Dine Festival 2025

HONG KONG, Oct. 20, 2025 (GLOBE NEWSWIRE) -- This month, Hong Kong welcomes one of Asia’s most anticipated culinary events. From 23 to 26 October 2025, the Hong Kong Wine & Dine Festival will be transforming the Central Harbourfront into an epicurean festival of masterful dishes, innovative wine pairings and high-profile collaborations. Guests can look forward to the return of signature highlights, from the BEA Grand Wine Pavilion – showcasing rare wine vintages and emerging global discoveries – to the Tasting Room, where acclaimed chefs unveil exclusive limited-time creations. And you won’t want to miss Towngas Gourmet Avenue, which brings together…

  • Technology Innovation
  • 20/10/2025
  • 19:16
OMDIA

Omdia: AMOLED 2H25 Display Revenues to Reach $29 Billion, Falling Short of 2H24

LONDON--BUSINESS WIRE-- Global AMOLED display revenues are projected to reach $53 billion by the end of 2025, a slight decline from $54 billion in 2024, according to Omdia’s latest Display Long-Term Demand Forecast Tracker. The stagnation comes despite a second-half recovery driven by new smartphone models and mobile PC panel growth, which was not enough to offset a challenging first half of the year marked by intense panel price competition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020728931/en/AMOLED quarterly revenues & growth AMOLED revenues are expected to grow by 19% quarter-on-quarter (QoQ) and 9% QoQ respectively in…

  • Environment
  • 20/10/2025
  • 19:11
Carbon Measures

Leading Global Businesses Unite to Launch Carbon Measures

New coalition to advance global carbon accounting framework and champion market-based solutions that drive emissions reductionsAmy Brachio, former Ernst & Young global vice chair and head of sustainability, named CEO NEW YORK--BUSINESS WIRE-- Carbon Measures, a new global coalition representing major businesses from diverse industries and geographies, launched today to establish a more accurate carbon accounting framework and drive market-based solutions to reduce emissions at the lowest cost. The coalition’s work will leverage sound science and the principles of financial accounting to help enable a ledger-based carbon accounting framework that is substantially more accurate, eliminates double counting and addresses current…

  • Business Company News, Employment Relations
  • 20/10/2025
  • 17:46
LSL Plus

Charles Sturt University Partners with LSL Plus to Advance Sustainable Long Service Leave Compliance

Key Facts: LSL Plus partners with Charles Sturt University to implement long service leave management solution Partnership aims to enhance LSL compliance and transparency across university workforce Cloud-based platform offers modular design, payroll integration and subscription-based service Solution helps organisations manage LSL liabilities, reduce compliance risk and streamline remediation processes Partnership represents significant advancement in LSL compliance for higher education sector Sydney, Australia – 20thOctober 2025– LSL Plus, Australia’s leading provider of sustainable long service leave compliance solutions, is proud to announce a landmark partnership with Charles Sturt University. The university has engaged LSL Plus to implement its long service…

  • Medical Health Aged Care
  • 20/10/2025
  • 17:11
Iksuda Therapeutics

Iksuda Presents Encouraging IKS014 Phase 1 Data at ESMO

New safety, efficacy and pharmacokinetic results presented from dose escalation portion of the studyAnti-tumour activity observed across all dose levels and in various tumour indications NEWCASTLE, England--BUSINESS WIRE-- Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of new data from its Phase 1 study of IKS014, a human epidermal growth factor receptor 2 (HER2)-directed ADC, in patients with advanced HER2+ solid tumours. The data was presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany. The Phase 1 study (NCT05872295) is a non-randomised, open-label, multicentre trial evaluating IKS014 in…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.